title: Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission.
abstract: We have measured the serum levels of soluble CD4, CD8 and IL-2R in 43 patients with AML in complete remission (AML-CR). The sCD8 levels of AML-CR patients (443.9 +/- 224.4 u/ml) were significantly high as compared to that of the normal controls (177.1 +/- 76.3 u/ml), p < 0.01. The sIL-2R levels of AML-CR patients were 715.0 +/- 646.3 u/ml, which significantly differed when compared to 322.1 +/- 65.7 u/ml for the normal controls, p < 0.01. However, the sCD4 levels of AML-CR patients were 9.6 +/- 4.7 u/ml, which did not differ from the 8.3 +/- 2.6 u/ml of the normal controls. The AML-CR patients showed significantly increased sCD8 and sIL-2R levels at all ranges during the remission from one to 188 months. The sCD8 levels and sIL-2R levels of the AML-CR patients showed a close correlation, p < 0.01. Further, the sCD8 levels and lymphokine activated killer cell cytotoxic activity showed a close correlation, p < 0.05. The presence of the activation of anti-tumor immunity may be related to the continuance of the remission in the AML-CR patients.
authors.affiliation: First Department of Internal Medicine, Nihon University, School of Medicine, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Iizuka
authors.forename: M
authors.initials: M
authors.lastname: Aiso
authors.forename: T
authors.initials: T
authors.lastname: Ohshima
authors.forename: S
authors.initials: S
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Horie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015704:CD4 Antigens / Q000097:blood*; D016827:CD8 Antigens / Q000097:blood*; D003561:Cytarabine / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000097:blood*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction
chemical_list: D015415:Biomarkers; D015704:CD4 Antigens; D016827:CD8 Antigens; D007376:Interleukin-2; D003561:Cytarabine; D011239:Prednisolone; D015122:Mercaptopurine; D003630:Daunorubicin